arrow
Z

Zhiqiang Hu

fudan university
H指数:45
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study

替雷利珠单抗联合仑伐替尼和GEMOX方案治疗不可切除的局部晚期胆道癌的转化治疗(ZSAB-TransGOLP):一项多中心、前瞻性、Ⅱ期研究

2025-08-290
PRE
Corrigendum to “CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling” [Cancer Lett. 358 2015 Pages 124–135]

勘误:“CXCR2/CXCL5轴通过激活PI3K/Akt/GSK-3β/Snail信号通路促进肝癌细胞的上皮-间质转化” [Cancer Lett. 358 2015 第124-135页]

2025-07-280
PRE
Assessing predictions on fitness effects of missense variants in HMBS in CAGI6
2024-08-070
PRE
Ef fi cacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
2024-05-015
OAAI